Affiliations: [a] Laboratory of Cancer Genetics, Greater Poland Cancer Center, Poznan, Poland | [b] European Center of Bioinformatics and Genomics (ECBaG), Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland | [c] Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland | [d] Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, USA | [e] Department of Head and Neck Surgery, Greater Poland Cancer Center, Poznan, Poland
Correspondence:
[*]
Corresponding authors:
Tomasz Kolenda,
Laboratory of Cancer Genetics,
Greater Poland Cancer Center,
Garbary 15, 61-866 Poznań, Poland.
E-mail: [email protected];
Katarzyna M. Lamperska,
Laboratory of Cancer Genetics,
Greater Poland Cancer Center,
Garbary 15, 61-866 Poznań, Poland.
E-mail: [email protected]
Abstract: BACKGROUND: The necessity of prediction and treatment outcome
improvement of HNSCC needs to find new biomarkers. miRNAs seem to be good
candidate for that. OBJECTIVE: Analysis of selected 5 miRNAs (let-7d, miR-18a,
miR-21, miR-205 and miR-375) as potential biomarkers that allows to
distinguish tumor and healthy tissue taken from HNSCC patients. METHODS: Tumor and normal epithelial tissues were obtained from 75
HNSCC patients to analyze selected miRNAs. RESULTS: Analysis indicated significant increase of miR-21 and
miR-205 in tumor when compared with healthy tissue (p= 0.0069 and p= 0.0029,
respectively). There was a significant correlation between
let-7d and miR-18a. let-7d was down-regulated in 34.67% cases, miR-18a in
29.33%, miR-21 in 20%, miR-205 in 30.67% and miR-375 in 52%
cases. At the same time over-expression of let-7d was detected in 18.67%
cases, miR-18a in 22.67%, miR-21 in 48%, miR-205 in 41.33% and
miR-375 in 52% cases. There was no correlation between miRNA expression
and clinical data and the course of illness. CONCLUSION: Our study indicated that miR-21 and miR-205 can be
used to analyze the clarity of surgical margins and that concomitant changes
in the expression of let-7 and miR-18a in tumor tissues might represent
important future markers indicating the biology of HNSCC. These observations
will help with developing personalization for HNSCC patients' treatment.
